文献速递核素与放射性配体治疗神经核医学

低剂量替莫唑胺选择性增加胶质母细胞瘤血管通透性、肿瘤微环境穿透及全身性锕-225 α粒子树枝状聚合物-放射性偶联物的杀伤潜力从而提高疗效

Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-14

在免疫健全的原位GL261-C57BL/6小鼠胶质母细胞瘤模型中,先给予低剂量标准治疗替莫唑胺再全身注射锕-225树枝状聚合物-放射性偶联物,可选择性增加肿瘤血管通透性;在9.7±5.7mm3脑肿瘤小鼠中,该联合方案较单用偶联物显著改善生存(平均生存44天 vs 39天,p=0.0017),且未引起长期(11个月)毒性。

要点

  • 低剂量替莫唑胺后24小时全身给予锕-225树枝状聚合物-放射性偶联物,肿瘤吸收剂量增加33%而不改变正常器官(含脑)剂量。
  • 联合治疗组平均生存44天,优于单用偶联物39天(p=0.0017)、单用替莫唑胺31天及未治疗30天(p<0.001)。
  • 在所用活度下未观察到长期(11个月)毒性。

核心结论

  • 本研究证明锕-225树枝状聚合物-放射性偶联物作为胶质母细胞瘤全身α粒子放疗具有潜力与安全性,并可被低剂量替莫唑胺增强。

研究设计与样本

  • 在免疫健全的原位GL261-C57BL/6小鼠胶质母细胞瘤模型中,评估全身注射锕-225树枝状聚合物-放射性偶联物在给予低剂量标准治疗替莫唑胺后的疗效。

主要发现

  • 在荷9.7±5.7mm3脑肿瘤小鼠中,替莫唑胺注射后24小时全身给予偶联物,在未引起长期(11个月)毒性的活度下,较单用偶联物显著改善生存(平均生存44天 vs 39天,p=0.0017),也优于单用替莫唑胺(31天)及未治疗动物(30天)(p<0.001)。
  • 化疗后注射偶联物使肿瘤吸收剂量显著增加33%,而不改变正常器官(包括脑)的剂量测定。
  • 以GL261球体作为模型肿瘤无血管区,显示偶联物穿透增强,提示其可能更深入穿透肿瘤。
  • 两种模式作用于同一癌细胞时形成更致命的组合。

关键数值与推荐

  • 联合组平均生存44天 vs 单用偶联物组39天(p=0.0017)。
  • 联合组平均生存44天 vs 单用替莫唑胺组31天及未治疗组30天(p<0.001)。
  • 化疗后给予偶联物使肿瘤吸收剂量增加33%,正常器官(含脑)剂量测定不变。
  • 长期毒性观察期为11个月。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The poor prognosis of glioblastoma is mostly due to the relatively low tumor vascular permeability to therapeutics, the tumor's vicinity to the brain, that limits treatment aggressiveness, and/or drug resistance. METHODS: In this study, the efficacy of systemically injected actinium-225 dendrimer-radioconjugates was evaluated in an immune-competent orthotopic GL261-C57BL/6 mouse model after administration of low-dose, standard-of-care temozolomide, that selectively increased the tumor vascular permeability to dendrimer-radioconjugates. Alpha-particles' short range in tissue combined with the dendrimers' selective uptake by glioblastomas, could limit the irradiation of the neighboring brain, while the complex double-strand DNA breaks caused by α-particles were expected to be largely impervious to resistance by cancer cells. RESULTS: On mice bearing 9.7 ± 5.7mm3 brain tumors, at activities that did not cause long-term (11-months) toxicities, dendrimer-radioconjugates, that were systemically-administered 24-hours after injection of temozolomide, significantly improved survival compared to dendrimer-radioconjugates alone (44 vs. 39 days mean survival, p = 0.0017) and/or compared to temozolomide alone and/or to non-treated animals (31 and 30 days, p < 0.001). This was attributed to: (1) the noteworthy increase (by 33%) in tumor absorbed doses delivered by dendrimer-radioconjugates when injected after chemotherapy, without altering normal organ (including the brain's) dosimetry; (2) the potentially deeper tumor penetration of dendrimer-radioconjugates, suggested by the enhanced dendrimer penetration within GL261-spheroids, employed as model tumor-avascular regions; and/or (3) the formation of a more lethal cocktail when both modalities acted on same cancer cells. CONCLUSIONS: This study demonstrates the potential and safety of actinium-225 dendrimer-radioconjugates as a systemic α-particle radiotherapy for glioblastoma enhanced by low-dose temozolomide.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nair RR, Sarkar A, Hariharan P, et al. Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy. Eur J Nucl Med Mol Imaging. 2025. PMID: 40366390. doi:10.1007/s00259-025-07332-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。